

# Ministry of Health and Long-Term Care

## Ontario Public Drug Programs

### Drug Submission Status

#### Complete Streamlined Multiple-Source Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Pharmascience Inc.	Pms-Ramipril	Altace	ramipril	15mg	capsule	02343932
Teva Canada Limited	Novo-Atomoxetine	Strattera	atomoxetine hydrochloride	10mg	capsule	02314541
Teva Canada Limited	Novo-Atomoxetine	Strattera	atomoxetine hydrochloride	18mg	capsule	02314568
Teva Canada Limited	Novo-Atomoxetine	Strattera	atomoxetine hydrochloride	25mg	capsule	02314576
Teva Canada Limited	Novo-Atomoxetine	Strattera	atomoxetine hydrochloride	40mg	capsule	02314584
Teva Canada Limited	Novo-Atomoxetine	Strattera	atomoxetine hydrochloride	60mg	capsule	02314592

Updated: December 21, 2010

